Equities Analysts Offer Predictions for TCRX FY2024 Earnings

by · The Markets Daily

TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) – Stock analysts at Wedbush increased their FY2024 earnings per share estimates for shares of TScan Therapeutics in a report released on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($1.09) per share for the year, up from their previous forecast of ($1.13). Wedbush has a “Outperform” rating and a $10.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share. Wedbush also issued estimates for TScan Therapeutics’ Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.96) EPS and FY2027 earnings at ($0.76) EPS.

TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.02. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The company had revenue of $0.54 million for the quarter, compared to analyst estimates of $1.55 million.

Several other research analysts have also weighed in on TCRX. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a report on Tuesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $12.00.

Read Our Latest Stock Analysis on TScan Therapeutics

TScan Therapeutics Price Performance

Shares of TCRX stock opened at $4.82 on Friday. The company has a quick ratio of 7.77, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a fifty-two week low of $3.73 and a fifty-two week high of $9.69. The stock’s 50-day moving average is $5.33 and its two-hundred day moving average is $6.51.

Institutional Investors Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of TScan Therapeutics by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock valued at $14,357,000 after buying an additional 20,000 shares during the period. Great Point Partners LLC boosted its position in shares of TScan Therapeutics by 8.0% in the 3rd quarter. Great Point Partners LLC now owns 1,016,375 shares of the company’s stock worth $5,062,000 after purchasing an additional 75,544 shares during the last quarter. abrdn plc boosted its position in shares of TScan Therapeutics by 27.2% in the 3rd quarter. abrdn plc now owns 371,655 shares of the company’s stock worth $1,851,000 after purchasing an additional 79,511 shares during the last quarter. Marshall Wace LLP boosted its position in shares of TScan Therapeutics by 60.8% in the 2nd quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock worth $1,799,000 after purchasing an additional 116,316 shares during the last quarter. Finally, Tocqueville Asset Management L.P. bought a new position in TScan Therapeutics during the first quarter worth about $1,685,000. 82.83% of the stock is owned by institutional investors and hedge funds.

Insider Activity at TScan Therapeutics

In other news, Director Barbara Klencke acquired 5,000 shares of TScan Therapeutics stock in a transaction on Friday, August 23rd. The stock was bought at an average price of $5.69 per share, for a total transaction of $28,450.00. Following the transaction, the director now owns 35,000 shares of the company’s stock, valued at $199,150. The trade was a 16.67 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Zoran Zdraveski sold 164,686 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the completion of the sale, the insider now owns 4,716 shares of the company’s stock, valued at $27,258.48. This represents a 97.22 % decrease in their position. The disclosure for this sale can be found here. Insiders acquired a total of 15,000 shares of company stock worth $82,550 in the last 90 days. 2.76% of the stock is owned by company insiders.

About TScan Therapeutics

(Get Free Report)

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

Featured Articles